Biomarkers Market Expands with Growth in Precision Medicine Research
The global biomarkers market was estimated at USD 81.04 billion in 2023 and is projected to reach USD 194.21 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13.36% from 2024 to 2030. Growth is being driven by the increasing prevalence of cancer, the growing importance of companion diagnostics, substantial research investments, and ongoing innovations in biomarker technologies.
### Key Market Trends & Insights
In 2023, North America led the market with a revenue share of 43.94%. Meanwhile, the Asia Pacific region is expected to register the fastest CAGR between 2024 and 2030. This growth is supported by rising cancer incidence, increased research funding, lower clinical trial costs in developing nations, and growing healthcare infrastructure.
By type, the safety biomarkers segment held the largest revenue share at 37.62% in 2023. However, the efficacy biomarkers segment is expected to grow at the fastest pace from 2024 to 2030. These biomarkers help predict patient responses to therapies, thereby reducing drug-development attrition rates.
On the product front, consumables (such as reagents and kits) dominated in 2023, driven by the rise of personalized and precision medicine. Meanwhile, services (such as biomarker-testing services) are forecasted to register strong growth during the forecast period.
In terms of application, the drug discovery & development segment led the market in 2023. Biomarkers help accelerate drug development by enabling better candidate selection and reducing clinical trial failures. The diagnostics segment is projected to exhibit the fastest CAGR from 2024 to 2030, fueled by growing research into early-stage disease detection biomarkers.
Among disease areas, cancer was the dominant segment in 2023 and is expected to maintain its leadership through 2030. This dominance reflects the high demand for rapid and accurate diagnostic tools in oncology. The immunological diseases segment is anticipated to grow most rapidly during the forecast period, driven by the rising incidence of immune-related disorders and increasing research into related biomarkers.
### Market Size & Forecast
– **2023 Market Size:** USD 81.04 billion
– **Projected 2030 Market Size:** USD 194.21 billion
– **CAGR (2024–2030):** 13.36%
Regionally, North America held the largest share in 2023, while Asia Pacific is expected to register the fastest growth.
*Order a free sample PDF of the Biomarkers Market Intelligence Study, published by Grand View Research.*
### Key Companies & Market Share Insight
The biomarkers market is characterized by rapid innovation, heavy investment in R&D, and a high degree of collaboration among industry players and academia. Major companies are focused on enhancing their portfolios through geographic expansion, product approvals, and infrastructure investment to efficiently process large sample volumes and launch advanced biomarker technologies.
#### Key Companies List
– Hoffmann-La Roche AG
– Epigenomics AG
– Abbott
– Thermo Fisher Scientific, Inc.
– General Electric
– Eurofins Scientific
– Johnson & Johnson Services, Inc.
– QIAGEN
– Bio-Rad Laboratories, Inc.
– Siemens Healthineers AG
– Merck KGaA
– PerkinElmer Inc.
– Agilent Technologies, Inc.
### Conclusion
In summary, the biomarkers market is poised for substantial expansion through to 2030, underpinned by a rise in chronic disease prevalence, advancements in precision diagnostics and therapeutics, and increasing global investment in healthcare innovation. North America remains the dominant region today, but Asia Pacific is set to become the fastest growing market.
Technological innovation, strategic partnerships, and a shift toward personalized and non-invasive diagnostics are key future drivers. Meanwhile, leading companies are actively expanding their capabilities and global reach to capture emerging opportunities in this dynamic market.
https://express-press-release.net/news/2025/11/13/1719990
You may also like
You may be interested
The New York Times
- Trump Stands in the Middle as Netflix and Paramount Vie for a Megadeal 2025 年 12 月 8 日 Michael M. Grynbaum
- Golden Globe 2026 Nominees: Full List Including ‘One Battle After Another’ 2025 年 12 月 8 日 Shivani Gonzalez
- Why Some Doctors Say There Are Cancers That Shouldn’t Be Treated 2025 年 12 月 8 日 Gina Kolata
- Jared Kushner Is Part of Paramount’s Bid for Warner Bros. Discovery 2025 年 12 月 8 日 Lauren Hirsch
- Syrians Celebrate Anniversary of Bashar al-Assad’s Fall 2025 年 12 月 8 日 Abdi Latif Dahir, Reham Mourshed and David Guttenfelder
- Planes, Trade and Nuclear Energy: Supreme Court Weighs Fate of Independent Regulators 2025 年 12 月 8 日 Stacy Cowley
- Justices Seem Ready to Give Trump More Power to Fire Independent Government Officials 2025 年 12 月 8 日 Ann E. Marimow
- A.I. Videos Have Flooded Social Media. No One Was Ready. 2025 年 12 月 8 日 Steven Lee Myers and Stuart A. Thompson
- FBI Agents Sue Patel After Being Fired Over Kneeling at George Floyd Protest 2025 年 12 月 8 日 Devlin Barrett
- Trump Plans $12 Billion Bailout to Aid Farmers Hit by Tariffs 2025 年 12 月 8 日 Alan Rappeport
Leave a Reply